Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide

Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide

Show other versions (1)

© 2019 American Pharmacists Association® Oral semaglutide, which has undergone multiple phase 3 clinical trials, represents the first oral biologic medication for type 2 diabetes in the form of a daily capsule. It provides similar efficacy compared with its weekly injection counterpart, but it deman...

Full description

Bibliographic Details
Main Authors: Abramson, Alex (Author), Halperin, Florencia (Author), Kim, Jane (Author), Traverso, Carlo Giovanni (Author)
Other Authors: Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor), Massachusetts Institute of Technology. Department of Mechanical Engineering (Contributor)
Format: Article
Language:English
Published: Elsevier BV, 2022-02-23T21:07:16Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items